Fidelity Disruptive Medicine ETF
FMED
3 hedge funds and large institutions have $19.9M invested in Fidelity Disruptive Medicine ETF in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
45.64% more ownership
Funds ownership: 0% → 45.64% (+46%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.1M |
| 2 |
Jane Street
New York
|
+$916K |
| 3 |
HI
Harbour Investments
Madison,
Wisconsin
|
+$1.03K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Fidelity Investments
Boston,
Massachusetts
| $19M | +$19.1M | +757,694 | New |
|
|
2
Jane Street
New York
| $915K | +$916K | +36,438 | New |
|
|
HI
3
Harbour Investments
Madison,
Wisconsin
| $1.03K | +$1.03K | +41 | New |
|
FMED Hedge Fund Activity: Q2 2023 in Review
3 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Fidelity Disruptive Medicine ETF (FMED) for Q2 2023, worth a combined $19.9M.
Buyers outnumbered sellers: 3 funds opened new FMED positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $19.1M.
- 3 institutional investors held Fidelity Disruptive Medicine ETF (FMED) as of Q2 2023, up from 0 in Q1 2023.
- Funds reported $19.9M of Fidelity Disruptive Medicine ETF stock for Q2 2023.
- 3 funds opened new Fidelity Disruptive Medicine ETF positions in Q2 2023 and 0 closed out, a net change of +3 holders.
- The largest Fidelity Disruptive Medicine ETF buyer in Q2 2023 was Fidelity Investments, an estimated $19.1M added.
Based on aggregated 13F filings for Q2 2023.